Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Hyperparathyroidism, Chronic Kidney Disease

In brief

The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal \[PTH\]to maintain normocalcemia in chronic kidney disease. This study will examine the hypothesis with measures of phosphate homeostasis and calcium reabsorption. A double-blind trial of the intestinal phosphate binder sevelamer carbonate will be employed to examine whether reductions in phosphate influx alter distal nephron phosphate concentration and the \[PTH\] required for calcium reabsorption in the expected manner.

Key facts

Study ID

NCT01191762

Run by

Kenneth R. Phelps, M.D.

People needed

30

Starts

2010-04-01

Expected to finish

2013-04-01

Last updated by the study team

2016-11-01

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• eGFR < 60 ml/min
• age at least 18 years

You may not qualify if…

• any primary parathyroid disease

Where it is running

• Stratton Veterans Affairs Medical Center — Albany, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.